Current thrombolytic therapy is limited by the number of patients who arrive both in time for therapy and with a known time of onset. In the Registry of the Canadian Stroke Network, 15% of ischemic stroke patients awoke with their deficits and these patients had poorer outcomes than those with stroke-whileawake.
However, mRI is globally limited by access and patient compatibility. 5 Computed tomogram perfusion is probably less limited by patient factors but radiation dose and contrast load are important considerations in deciding on acute perfusion imaging. We have previously shown that patients treated with intraarterial thrombolysis, an average of slightly more than five hours from onset, only benefited from therapy when the baseline noncontrast CT (NCCT) scan showed minimal or no damage as shown by an ASPeCTS score > 7. 6, 7 This same relationship cannot be shown for the under-3-hour time window with Iv thrombolysis. 8 However, it is clear that out to six hours from symptom onset, significant areas of early ischemic change (ASPeCTS < 4) are associated with a much greater risk of PH2 hemorrhage and death. 9 We hypothesized that patients with a favorable baseline NCCT scan defined by an ASPeCTS > 5, an intracranial arterial occlusion defined by transcranial doppler ultrasound (TCD) or CT angiogram and disabling stroke symptoms were candidates for thrombolytic therapy. We tested the safety of our hypothesis among patients who awoke with stroke symptoms.
METHODS
The study was approved by the Calgary Health Region ethics Board. All patients or their surrogate provided informed consent. The study was conducted at a single centre over 2.5 years (2006-2009). We educated our emergency Department triage staff to alert the stroke team for any patient who awoke with a stroke deficit. Patients were screened by the stroke fellow or stroke physician on-call.
Inclusion criteria were a last known well time within 12 hours of emergency department (eD) arrival, stroke-on-awakening, a disabling stroke, a demonstrated extra-or intracranial arterial occlusion (as the cause of stroke symptoms) on CT angiography or TCD (defined by the TIBI criteria). 10 Initially, the NCCT had to show an ASPeCTS score > 7; half-way through the study we relaxed this criterion to ASPeCTS > 5 and included patients who simply had an undefined time of onset (but still within 12 hours) to improve recruitment. NCCT scans had to be scored by the attending physician and by a second expert reader (neuroradiologist oR stroke neurologist) who did not know the case to ensure that the patient met ASPeCTS criteria. Patients with obvious hypodensity, defined as grey matter hypodensity with qualitative lower attenuation than normal appearing white matter, were excluded, even if the ASPeCTS score was greater than 5. Transcranial doppler ultrasound studies were conducted by the stroke fellow or staff. The CT angiograms are performed routinely as part of the standard stroke imaging assessment. We diagnosed an arterial occlusion by assessing both the CTA source images and thick slab axial and coronal reconstructed images for an intraluminal filling defect. All patients had to be treated within 60 minutes of the CT scan.
Patients were excluded if they had any of the standard thrombolytic contraindications defined by the NINDS tPA Stroke Trial. 11 All patients had a follow-up brain CT scan at 24 hours which was interpreted by a neuroradiologist. Clinical outcomes were assessed at 90 days by personnel blinded to the clinical course, certified in the NIH stroke scale score.
Standard descriptive statistics were used to assess the data. All analyses were conducted with STATA (Statacorp, College Station, TX).
RESULTS
Recruitment was hampered by the lack of direct referral by emS of patients with stroke-on-awakening. Such patients, according to the local Calgary emS stroke screen are taken to the nearest hospital rather than bypassed to our stroke centre, because they are beyond the usual thrombolytic window. The change in inclusion criteria by lowering the ASPeCTS threshold from ASPeCTS > 7 to ASPeCTS > 5 and including more than just stroke-on-awakening patients allowed us to finish the trial. The justification for lowering the ASPeCTS threshold was based upon analysis of the NINDS tPA trial and the eCASS-2 trial where an ASPeCTS by treatment interaction was not shown. 8, 9 However, safety concerns were shown with very low ASPeCTS scores (ASPeCTS < 4). We chose to include patients who suffered strokes while awake but still had an undefined time of onset within the overall 12-hour safety window. A total of five patients were included with an ASPeCTS of six or seven and two patients were not stroke-on-awakening cases but instead unwitnessed stroke.
Patient characteristics are described in Table 1 . Among 89 screened patients, 20 were successfully treated. Among excluded patients, the primary reasons were: (a) 29 had an ASPeCTS ≤ 5; (b) 19 had well-evolved infarcts on CT; (c) 17 had a mRS > 2; (d) 10 had no demonstrable arterial occlusion or were too clinically mild (ie. not disabled by their stroke) to warrant treatment. Among the 20 treated patients, the number and location of arterial occlusions is described in Table 2 .
Two patients (10%) died due to massive carotid territory stroke and two patients (10%) died of stroke complications. No patient suffered symptomatic intracranial hemorrhage and there were two patients (10%) with asymptomatic ICH (petechial hemorrhage). good outcome (mRS 0-1) was observed in nine patients (45%) [Figure] . Protocol violations occurred in three patients, in whom, on review there was no vessel occlusion on THe CANADIAN JoURNAl oF NeURologICAl SCIeNCeS 18 lSW = last seen well; SBP = systolic blood pressure; mm = millimole; bASPeCTS = baseline Alberta Stroke Program early CT score; bNIHSS = baseline National Institutes of Health Stroke Scale score The occluded vessels were: baseline CT angiography in two. Both of these patients had underlying internal carotid artery (ICA) stenosis. A third patient was treated beyond the 12 hour window after discussion with the medical monitor. All three patients are included in the analysis.
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Interpretation
This study demonstrates that patients with stroke-onawakening or undefined time of onset can be safely treated with intravenous tPA based upon simple NCCT and vascular imaging. We believe that it is possible to simplify the concept of using multimodal mR or CT perfusion imaging to assess penumbra and degree of ischemic brain damage, to select patients for thrombolysis.
The use of a NCCT and CT angiogram or TCD has significant advantages in reducing and simplifying acute stroke imaging. This approach may be successful for a several reasons. First, we know that the region of early hypodensity on CT represents early ischemic edema which is a marker of irreversibly injured brain tissue; 12 hence, the ASPeCTS score estimates the core of ischemia. This observation is confirmed by the linear relationship between CT ASPeCTS and the mR diffusion weighted image ASPeCTS in major ischemic stroke within six hours of onset. 5 The high specificity and good sensitivity of noncontrast CT for evaluation of the ischemic brain 13, 14 is widely underappreciated in the stroke community, in part because it takes a careful clinician to assess the baseline CT scan. Second, the degree of ischemic change is clearly correlated with the immediate risk of thrombolysis. 15 Therefore, the baseline NCCT can both include the diagnosis of ischemic stroke (rather than only excluding hemorrhage) and it can allow us to determine the safety of immediate thrombolysis. Third, advances in TCD and CT angiography have allowed us to make rapid, accurate vascular diagnoses. Finally, the clinical condition of the patient tells us how much and what tissue is not functioning. A large deficit with limited core infarct, as assessed by ASPeCTS, implies a perfusion-diffusion mismatch and the potential for tissue salvage with reperfusion. Therefore, in the setting of a vascular occlusion and a favourable NCCT appearance (minimal eIC or high ASPeCTS score), the probability that there is salvageable penumbra is high. Such patients are ideal candidates for stroke thrombolysis.
Although only ~20% of the screened patients were eligible for inclusion into our study, the implication is that some patients with stroke-on-awakening suffer their events immediately or just before they wake up, such that their onset-to-treatment time is actually much less than their last-seen-well-to-treatment time. The presence of absence of penumbra is not purely timedependent; other factors such as the collateral circulation and tissue susceptibility to ischemia are also likely relevant.
We chose not to apply intra-arterial therapy primarily in this cohort. While it has pervaded the stroke literature that intraarterial approaches are appropriate for later time windows, it is simply not true that intra-arterial thrombolytic therapy is safer than intravenous therapy. major adverse events are more common with intra-arterial therapy and our goal was the assessment of safety.
This paradigm is not unique. Indeed, the ingrained concept of "time is brain" is not pathophysiologically valid. 16, 17 This is being increasingly recognized as other studies are now examining the role of imaging in extended time windows, to identify patients for thrombolysis. A reminder of the risk of hemorrhage came with the cessation of the AbeSTT-2 study in which the stroke-on-awakening cohort was stopped early for safety reasons (presumedly symptomatic hemorrhage). Two other multicentre studies, the vASTT trial, assessing a new thrombolytic agent (v10153) and the DIAS-2 study (assessing desmoteplase) can include patients with stroke-on-awakening as long as they fit within the overall nine hour window. other studies are assessing the role of the mRI-defined perfusiondiffusion mismatch paradigm as a patient selection tool with low-dose Iv therapy and gP2b3a inhibitors (RoSIe trial) and using the meRCI concentric retriever (mR ReSCUe). Two planned randomized trials for patients with stroke on awakening should begin within the next year [WAKe-UP -NCT01525290 and eXTeND -NCT01580839] and provide us with definitive data on the use of the tissue window for patient selection for stroke thrombolysis. 
